Shares of Hims & Hers Health Inc. (NYSE:HIMS) rose 3.9% on Thursday following the company announcement that generic semaglutide will be available through its platform for eligible customers in Canada.
The company said it will offer personalised treatment plans starting at CAD 149 per month. Those plans pair medication access with unlimited support from a Care Team, nutrition and lifestyle guidance, and Canadian medical expertise, the company said.
Health Canada has authorized the sale of generic semaglutide for the management of Type 2 diabetes. The medication may also be prescribed off-label for weight management, at the discretion of a licensed healthcare provider acting within clinical judgment, the company said.
Hims & Hers highlighted the prevalence of overweight and obesity among Canadian adults, noting nearly two-thirds fall into those categories. The company identified cost as a persistent barrier preventing broader access to GLP-1 treatments.
Commenting on the launch, Dr. Sandy Van, Obesity Medicine Specialist and Chief Medical Officer at Hims & Hers Canada, said: "Generics have always played a critical role in expanding access to medicines that change lives. Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient."
Under the announced programme, eligible Canadian customers will be offered personalised care plans that may include GLP-1 options. These plans are billed as combining medication access with ongoing Care Team availability and evidence-informed resources focused on nutrition, movement, and sleep. The company said all Canadian customers will be connected with Canadian providers.
Austin Kouri, General Manager at Hims & Hers Canada, said the market introduction of generic semaglutide is intended to provide a more affordable path to treatment for Canadians. The company also noted a limitation in its current services: Hims & Hers Canada Inc. does not currently offer access to treatment services for Type 2 diabetes.
Market reaction to the announcement was reflected in the stock move, with the shares advancing shortly after the availability news was released. The offering emphasises an integrated service model that combines medication access with remote clinical support and lifestyle resources targeted at customers in Canada.
Details provided by the company indicate a focus on cost reduction and continuity of care through the Care Team model, but the firm also flagged the specific service scope related to Type 2 diabetes treatment as not being part of its current offering in Canada.